DDX5和DDX17在卵巢癌组织中的表达及对人卵巢癌细胞系SKOV3增殖和耐药的影响  

Expression of DDX5 and DDX17 in ovarian cancer tissues and their effects on proliferation and drug resistance of human ovarian cancer cell line SKOV3

作　　者：黄洁 李润博 郭建新 韩健 HUANG Jie;LI Runbo;GUO Jianxin;HAN Jian(Department of Obstetrics and Gynecology,Army Medical Center of PLA,Army Medical University,Chongqing 400042,China)

机构地区：[1]陆军军医大学陆军特色医学中心妇产科,重庆400042

出　　处：《基础医学与临床》2023年第8期1247-1253,共7页Basic and Clinical Medicine

基　　金：陆军军医大学优秀人才库项目(B-3271)。

摘　　要：目的分析DDX5和DDX17在卵巢癌中的表达水平及与患者生存期的关系,并研究其对人卵巢癌细胞系SKOV3增殖及耐药的影响。方法选取40例卵巢癌和27例正常卵巢上皮标本,采用RT-qPCR检测DDX5和DDX17的表达;应用TCGA数据库分析卵巢癌中DDX5和DDX17与患者生存预后的关系;用慢病毒介导的DDX5-shRNA和DDX17-shRNA下调SKOV3细胞中DDX5和DDX17的表达,Western blot验证敲降效果,CCK8法检测细胞增殖能力及对紫杉醇和卡铂的药物敏感性。结果与正常卵巢上皮相比,卵巢癌组织中DDX5的表达升高,而DDX17的表达明显降低(P<0.05);高表达DDX5的卵巢癌患者具有较短的无进展生存期和总生存期,而高表达DDX17的卵巢癌患者则有更长的无进展生存期和总生存期;DDX5表达下调抑制SKOV3细胞增殖,而DDX17表达下调后促进增殖;DDX5表达下调后SKOV3细胞对紫杉醇和卡铂的药物敏感性明显增加,而DDX17表达下调后SKOV3细胞对紫杉醇和卡铂的药物敏感性变化不明显。结论DDX5和DDX17能够调节卵巢癌细胞系的增殖与耐药,可能是卵巢癌发生发展中的重要调节因子。Objective To analyze the expression of DDX5 and DDX17 in ovarian cancer and their relationship with patient survival,and to study the effects of DDX5 and DDX17 on proliferation and drug resistance of ovarian cancer cell line SKOV3.Methods The expression of DDX5 and DDX17 was detected by RT-qPCR in tissue samples from 40 cases of ovarian carcinoma and 27 controls.TCGA database was used to analyze the relationship between DDX15/DDX17 and survival prognosis of ovarian cancer patients.The expression of DDX5 and DDX17 in SKOV3 was down-regulated by lentivirus-mediated DDX5-shRNA and DDX17-shRNA.Western blot was used to verify the knockdown effect,and CCK8 was used to detect cell proliferation and resistance to paclitaxel and carboplatin.Results Compared with normal ovarian epithelium,the expression of DDX5 in samples from ovarian carcinoma was increased,while that of DDX17 was decreased significantly(P<0.05);Ovarian cancer patients with high DDX5 expression had shorter progression-free survival and overall survival time,while those with high DDX17 expression had longer progression-free survival and overall survival time.Down-regulated DDX5 expression inhibited the SKOV3 cells proliferation,while down-regulated DDX17 expression promoted SKOV3 cells proliferation.The drug sensitivity of SKOV3 cells to paclitaxel and carboplatin was significantly increased after the down-regulation of DDX5 expression,while the drug sensitivity of SKOV3 cells to paclitaxel and carboplatin was not significantly changed after the down-regulation of DDX17 expression.Conclusions DDX5 and DDX17 regulate proliferation and drug resistance of ovarian cancer cells,and are potential regulatory factors functioning in ovarian cancer.

关 键 词：卵巢癌 DDX5 DDX17 增殖 耐药 

分 类 号：R73[医药卫生—肿瘤]